WHWK
What one share of Whitehawk Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to approval, launch, and commercialization.
Whitehawk Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.10 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.96 |
| Cash and investments | $1.50 |
| Book value | $3.21 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$24.53 | $0.13 | −$0.16 | — | −$69.48 |
| 2017 | — | −$1.03 | $0.00 | −$0.87 | — | $0.64 |
| 2018 | $0.59 | −$0.31 | $0.00 | −$0.17 | — | $1.45 |
| 2019 | $0.00 | −$0.57 | $0.01 | −$0.59 | — | −$0.22 |
| 2020 | $5.51 | −$1.76 | $0.01 | −$5.00 | — | −$4.89 |
| 2021 | $1.57 | −$12.41 | $0.01 | −$2.52 | — | — |
| 2022 | $0.68 | −$2.69 | $0.02 | −$2.22 | — | $6.48 |
| 2023 | $0.90 | −$2.44 | $0.15 | −$2.36 | — | $4.28 |
| 2024 | $0.96 | −$2.36 | $0.06 | −$2.26 | — | $2.13 |
| 2025 | $0.12 | −$0.33 | $0.01 | −$1.58 | — | $2.89 |